Skip to content

The efficacy and safety of remimazolam injection for painless abortion

The efficacy and safety of remimazolam injection for painless abortion

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034121
Enrollment
Unknown
Registered
2020-06-24
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless abortion anesthesia

Interventions

group propofol:IV propofol
group remimazolam:IV remimazolam

Sponsors

the Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Aged 18-45 years; 2) ASA score is level I or II; 3) Patients receiving painless abortion in outpatient department; 4) 18 kg/m2 < BMI < 30kg/m2; 5) Clearly understand, voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have been determined to have difficulty in respiratory management (grade IV for improved Markov score); 2) Anemia or thrombocytopenia, Hb = 160 at screening stage) MmHg and/or screening diastolic blood pressure >= 100 mmHg); 5) Systolic pressure of sitting position <=90 mmHg during screening; 6) Lactating women; 7) Participated in other drug clinical trials as a subject within the last 3 months; 8) Allergic or contraindicated to benzodiazepines, opioids, propofol, lidocaine and their drug components; 9) The investigator considers it inappropriate for the patient to participate in this study.

Design outcomes

Primary

MeasureTime frame
MOAA/S SCORE;

Countries

China

Contacts

Public ContactHu Tingju

Department of Anesthesiology, the Affiliated Hospital of Guizhou Medical University

363818952@qq.com+86 18798000325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026